Pricing Log in Create free account
Friday 6 November 2026 Export CRL’s income statement to Excel — free account

Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.

Revenue
−2.20%
EPS
+530.3%
Free cash flow
+16.3%
Total debt
+11.8%

Quarter to September 2026, against a year earlier

313.98 12.31 −3.77%
Market cap
$14.9B
P/E
300×
Fwd P/E
89.2×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Charles River Laboratories International, Inc. (CRL) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Charles River Laboratories International, Inc. (CRL) trades at a EV/EBITDA of 31.2×. Over the past ten years it has ranged from 9.3× (April 2025) to 36.6× (October 2026); the current reading is higher than 99% of that period. That is above the Diagnostics & Research industry median of 23.4× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 19.9× 38.77%
FY2024 14.3× (7.06%)
FY2023 15.4× 8.56%
FY2022 14.2× (43.20%)
FY2021 25.0× 18.24%
FY2020 21.2× 27.84%
FY2019 16.6× 18.36%
FY2018 14.0× (5.89%)
FY2017 14.9× 14.82%
FY2016 12.9× (12.97%)

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 29.6× 22.72%
Jun 2026 24.1× 29.18%
Mar 2026 18.6× (6.31%)
Dec 2025 19.9× 61.00%
43 more quarters

Against its own ten years

Low 9.3× High 36.6×
Ten-year median 15.1×
Current reading's percentile 99

EV/EBITDA against peers

Company EV/EBITDA
GH Guardant Health, Inc. compare n/m
DGX Quest Diagnostics Incorporated compare 14.2×
LH Labcorp Holdings Inc. compare 15.6×
QGEN QIAGEN N.V. compare 17.4×
ICLR ICON PLC compare 17.9×
RVTY Revvity Inc. compare 25.1×
ILMN Illumina, Inc. compare 26.4×
MEDP Medpace Holdings, Inc. compare 27.0×
CRL Charles River Laboratories International, Inc. 31.2×
Diagnostics & Research industry median 23.4×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on CRL